keyword
MENU ▼
Read by QxMD icon Read
search

tocilizumab

keyword
https://www.readbyqxmd.com/read/28927784/safety-and-efficacy-of-blinatumomab-in-combination-with-a-tyrosine-kinase-inhibitor-for-the-treatment-of-relapsed-philadelphia-chromosome-positive-leukemia
#1
Rita Assi, Hagop Kantarjian, Nicholas J Short, Naval Daver, Koichi Takahashi, Guillermo Garcia-Manero, Courtney DiNardo, Jan Burger, Jorge Cortes, Nitin Jain, William Wierda, Salim Chamoun, Marina Konopleva, Elias Jabbour
OBJECTIVE: The treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia has been revolutionized with the introduction of tyrosine kinase inhibitors (TKIs) and the combination of these agents with chemotherapy. Blinatumomab is a bispecific anti-CD3/CD19 monoclonal antibody with clinical activity as single-agent in the relapsed setting and independent of BCR-ABL1 mutational status, including T315I. The combination of blinatumomab with a TKI may further improve outcomes for this high-risk population, including higher eradication of minimal residual disease and minimize the use of chemotherapy...
August 18, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28922343/tocilizumab-actemra-for-giant-cell-arteritis
#2
(no author information available yet)
No abstract text is available yet for this article.
September 25, 2017: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/28916714/interleukin-6-blockade-raises-ldl-via-reduced-catabolism-rather-than-via-increased-synthesis-a-cytokine-specific-mechanism-for-cholesterol-changes-in-rheumatoid-arthritis
#3
Jamie Robertson, Duncan Porter, Naveed Sattar, Chris J Packard, Muriel Caslake, Iain McInnes, David McCarey
OBJECTIVES: Patients with rheumatoid arthritis (RA) have reduced serum low-density lipoprotein cholesterol (LDL-c), which increases following therapeutic IL-6 blockade. We aimed to define the metabolic pathways underlying these lipid changes. METHODS: In the KALIBRA study, lipoprotein kinetic studies were performed on 11 patients with severe active RA at baseline and following three intravenous infusions of the IL-6R blocker tocilizumab. The primary outcome measure was the fractional catabolic rate (FCR) of LDL...
September 15, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28913368/erratum-to-low-baseline-interleukin-17a-levels-are-associated-with-better-treatment-response-at-12-weeks-to-tocilizumab-therapy-in-rheumatoid-arthritis-patients
#4
Sang Jin Lee, Won Park, Sung Hwan Park, Seung-Cheol Shim, Han Joo Baek, Dae-Hyun Yoo, Hyun Ah Kim, Soo Kon Lee, Yun Jong Lee, Young Eun Park, Hoon-Suk Cha, Jin Kyun Park, Eun Young Lee, Eun Bong Lee, Yeong Wook Song
[This corrects the article DOI: 10.1155/2015/487230.].
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/28910968/efficiency-of-antibody-therapy-in-demyelinating-diseases
#5
Tetsuya Akaishi, Ichiro Nakashima
Monoclonal antibody therapy is a new treatment strategy for many types of diseases including cancers and autoimmune diseases, realizing a high efficacy and tolerability. In multiple sclerosis (MS) and neuromyelitis optica (NMO) spectrum disorders, several monoclonal antibodies have been suggested to decrease the incidence of clinical relapse and the disease activity. In MS, anti-α4 integrin (natalizumab), anti-CD52 (alemtuzumab), anti-CD25 (daclizumab) and anti-CD20 (ocrelizumab) have been shown to effectively reduce the relapses in randomized controlled trials and have been approved by the Food and Drug Administration...
July 1, 2017: International Immunology
https://www.readbyqxmd.com/read/28905861/giant-cell-arteritis-and-polymyalgia-rheumatica-current-challenges-and-opportunities
#6
REVIEW
Christian Dejaco, Elisabeth Brouwer, Justin C Mason, Frank Buttgereit, Eric L Matteson, Bhaskar Dasgupta
The fields of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) have advanced rapidly, resulting in a new understanding of these diseases. Fast-track strategies and improved awareness programmes that prevent irreversible sight loss through early diagnosis and treatment are a notable advance. Ultrasonography and other imaging techniques have been introduced into routine clinical practice and there have been promising reports on the efficacy of biologic agents, particularly IL-6 antagonists such as tocilizumab, in treating these conditions...
September 14, 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28903416/overriding-tki-resistance-of-renal-cell-carcinoma-by-combination-therapy-with-il-6-receptor-blockade
#7
Kei Ishibashi, Tobias Haber, Ines Breuksch, Susanne Gebhard, Takashi Sugino, Hitoshi Kubo, Junya Hata, Tomoyuki Koguchi, Michihiro Yabe, Masao Kataoka, Soichiro Ogawa, Hiroyuki Hiraki, Tomohiko Yanagida, Nobuhiro Haga, Joachim W Thüroff, Dirk Prawitt, Walburgis Brenner, Yoshiyuki Kojima
Metastatic renal cell carcinoma (RCC) is a tumor entity with poor prognosis due to limited therapy options. Tyrosine kinase inhibitors (TKI) represent the standard of care for RCCs, however a significant proportion of RCC patients develop resistance to this therapy. Interleukin-6 (IL-6) is considered to be associated with poor prognosis in RCCs. We therefore hypothesized that TKI resistance and IL-6 secretion are causally connected. We first analyzed IL-6 expression after TKI treatment in RCC cells and RCC tumor specimens...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28895041/unmet-needs-in-the-pathogenesis-and-treatment-of-vasculitides
#8
REVIEW
Francesco Muratore, Giulia Pazzola, Alessandra Soriano, Nicolò Pipitone, Stefania Croci, Martina Bonacini, Luigi Boiardi, Carlo Salvarani
Despite the progress in the last years on the field of vasculitides, there are several unmet needs regarding classification, disease activity assessment, predictors of flares and complications, and type of treatment for the different forms. The 1990 American College of Rheumatology (ACR) classification criteria currently used to define giant cell arteritis and Takayasu arteritis were designed to discriminate between different types of vasculitides but not to differentiate vasculitis from other disorders. Recently, efforts have been made to overcome the shortcomings of the ACR criteria...
September 11, 2017: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/28887113/primary-month-6-outcomes-of-the-stop-uveitis-study-evaluating-the-safety-tolerability-and-efficacy-of-tocilizumab-in-patients-with-non-infectious-uveitis
#9
Yasir Jamal Sepah, Mohammad Ali Sadiq, David S Chu, Mark Dacey, Ron Gallemore, Pouya Dayani, Mostafa Hanout, Muhammad Hassan, Rubbia Afridi, Aniruddha Agarwal, Muhammad Sohail Halim, Diana V Do, Quan Dong Nguyen
PURPOSE: To report the primary end-point analyses of the safety and efficacy of two different doses of intravenous (IV) infusions of tocilizumab (TCZ), an IL-6 inhibitor, in eyes with non-infectious intermediate, posterior or pan-uveitis. DESIGN: Randomized, controlled, multicenter clinical trial. METHODS: STOP-Uveitis is a randomized, open-label safety, efficacy and bioactivity clinical trial conducted at 5 clinical centers across the United States...
September 5, 2017: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/28886955/successful-combined-targeting-of-b-and-plasma-cells-in-treatment-refractory-anti-nmdar-encephalitis
#10
Olafur Sveinsson, Mathias Granqvist, Yngve Forslin, Kaj Blennow, Henrik Zetterberg, Fredrik Piehl
We describe an extremely severe case of therapy refractory NMDA receptor encephalitis (NMDAe) in a 26-year-old woman. After rituximab, bilateral oophorectomy, repeated cycles of high dose methylprednisolone and plasma exchange, she received repeated cyclophosphamide, tocilizumab (interleukin-6 inhibitor) and finally bortezomib (plasma cell depleting drug) leading to remission after 204days in intensive care. Two years after disease onset her cognitive functions are still affected, but slowly improving and the cerebral atrophy has been partly reversed...
August 25, 2017: Journal of Neuroimmunology
https://www.readbyqxmd.com/read/28886017/b-cell-phenotype-and-igd-cd27-memory-b-cells-are-affected-by-tnf-inhibitors-and-tocilizumab-treatment-in-rheumatoid-arthritis
#11
Rita A Moura, Cláudia Quaresma, Ana R Vieira, Maria J Gonçalves, Joaquim Polido-Pereira, Vasco C Romão, Nádia Martins, Helena Canhão, João E Fonseca
BACKGROUND: The use of TNF-inhibitors and/or the IL-6 receptor antagonist, tocilizumab, in rheumatoid arthritis (RA) have pleiotropic effects that also involve circulating B-cells. The main goal of this study was to assess the effect of TNF-inhibitors and tocilizumab on B-cell phenotype and gene expression in RA. METHODS: Blood samples were collected from untreated early RA (ERA) patients, established RA patients under methotrexate treatment, established RA patients before and after treatment with TNF-inhibitors and tocilizumab, and healthy donors...
2017: PloS One
https://www.readbyqxmd.com/read/28880691/changes-in-serum-interleukin-6-levels-as-possible-predictor-of-efficacy-of-tocilizumab-treatment-in-rheumatoid-arthritis
#12
Motohiko Aizu, Ichiro Mizushima, Satoshi Nakazaki, Akikatsu Nakashima, Takashi Kato, Takashi Murayama, Shinichi Kato, Yasuo Katsuki, Kunihiro Ogane, Hiroshi Fujii, Kazunori Yamada, Hideki Nomura, Akihiro Yachie, Masakazu Yamagishi, Mitsuhiro Kawano
OBJECTIVES: We aimed to evaluate the association between the change in serum IL-6 during the clinical course of tocilizumab (TCZ) therapy and rheumatoid arthritis (RA) disease activity or occurrence of adverse events. METHODS: General laboratory data including serum IL-6 levels and physical findings were obtained every 4 weeks, and, in addition, at the time when any adverse events occurred. RESULTS: The proportion achieving Clinical Disease Activity Index (CDAI) remission at 52 weeks was significantly lower in 20 patients with serum IL-6 ≥ 30 pg/ml at 12 weeks than 24 patients with serum IL-6 < 30 pg/ml...
September 7, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28880689/prodromal-signs-and-symptoms-of-serious-infections-with-tocilizumab-treatment-for-rheumatoid-arthritis-text-mining-of-the-japanese-postmarketing-adverse-event-reporting-database
#13
Tatsuya Atsumi, Yoshiaki Ando, Shinichi Matsuda, Shiho Tomizawa, Riwa Tanaka, Nobuhiro Takagi, Ayako Nakasone
OBJECTIVE: To search for signs and symptoms before serious infection (SI) occurs in tocilizumab (TCZ)-treated rheumatoid arthritis (RA) patients. METHODS: Individual case safety reports, including structured (age, sex, adverse event [AE]) and unstructured (clinical narratives) data, were analyzed by automated text mining from a Japanese post-marketing AE-reporting database (16 April 2008-10 April 2015) assuming the following: treated in Japan; TCZ RA treatment; ≥1 SI; unable to exclude causality between TCZ and SIs...
September 7, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28880684/reduction-of-methotrexate-and-glucocorticoids-use-after-the-introduction-of-biological-disease-modifying-anti-rheumatic-drugs-in-patients-with-rheumatoid-arthritis-in-daily-practice-based-on-the-iorra-cohort
#14
Yoko Shimizu, Eiichi Tanaka, Eisuke Inoue, Kumi Shidara, Naoki Sugimoto, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi, Hisashi Yamanaka
OBJECTIVES: To evaluate usage patterns for methotrexate (MTX) and/or glucocorticoids in rheumatoid arthritis (RA) patients receiving biological disease-modifying antirheumatic drugs (bDMARDs) in daily practice. METHODS: Data from RA patients who commenced treatment with bDMARDs (infliximab [IFX], etanercept [ETN], tocilizumab [TCZ], or adalimumab [ADA]) from 2008 to 2010 were extracted from the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) database. The proportions of patients taking concomitant MTX and glucocorticoids and doses of these medications were evaluated before and 2 years after initiation of each bDMARD...
September 14, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28879047/treatment-of-polyarteritis-nodosa-with-tocilizumab-a-new-therapeutic-approach
#15
Aurélie Saunier, Nahéma Issa, Marie-Anne Vandenhende, Philippe Morlat, Marie-Sylvie Doutre, Fabrice Bonnet
We describe the effect of interleukin 6 (IL-6) blockade using tocilizumab (TCZ) for inducing and maintaining remission of refractory polyarteritis nodosa (PAN). Three patients with refractory PAN defined according to the American College of Rheumatology criteria were treated with TCZ infusions (8 mg/kg) on a monthly basis. All of them had severe cutaneous and articular involvement with elevated biological inflammatory markers. One suffered from a neuritis multiplex and one from renal and digestive damage...
2017: RMD Open
https://www.readbyqxmd.com/read/28878334/vasculitis-syndromes-tocilizumab-a-new-frontier-for-gca-therapy
#16
Matthew J Koster, Kenneth J Warrington
No abstract text is available yet for this article.
September 7, 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28868300/aa-amyloidosis-and-atypical-familial-mediterranean-fever-with-exon-2-and-3-mutations
#17
Junko Yabuuchi, Noriko Hayami, Junichi Hoshino, Keiichi Sumida, Tatsuya Suwabe, Toshiharu Ueno, Akinari Sekine, Masahiro Kawada, Masayuki Yamanouchi, Rikako Hiramatsu, Eiko Hasegawa, Naoki Sawa, Kenmei Takaichi, Takeshi Fujii, Kenichi Ohashi, Kiyoshi Migita, Takao Masaki, Yoshifumi Ubara
A 54-year-old Japanese man presented with recurrent abdominal pain, fever lasting >5 days, and renal failure. AA amyloidosis was proven by renal and gastric biopsy. Symptoms subsided with the administration of colchicine, but a subsequent recurrence of symptoms did not respond to colchicine. Mediterranean fever gene (MEFV) analysis showed that he was heterozygous for mutations in exon 2 (E148Q/R202Q) and exon 3 (P369S/R408Q), although he had none of the exon 10 mutations known to be closely related to AA amyloidosis...
May 2017: Case Reports in Nephrology and Dialysis
https://www.readbyqxmd.com/read/28861079/tocilizumab-contributes-to-the-inflammatory-status-of-mature-dendritic-cells-through-interleukin-6-receptor-subunits-modulation
#18
Daniel Meley, Audrey Héraud, Valerie Gouilleux-Gruart, Fabrice Ivanes, Florence Velge-Roussel
Tocilizumab, a humanized anti-IL-6 receptor α (IL-6Rα) is widely used in the treatment of a panel of pathologies such as adult and juvenile rheumatoid arthritis (RA) and the systemic form of juvenile idiopathic arthritis in children. Its indications are expected to be largely extended to other inflammatory diseases in close future. Dendritic cells (DCs) appear to be deeply involved in the immunopathology of these diseases, yet the effects of tocilizumab on these cells were poorly studied. In this study, we explored the effect of tocilizumab on the regulation of IL-6R subunits [gp130, soluble form of IL-6Rα (sIL-6Rα), and mIL-6Rα] in human monocyte-derived DCs...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28860565/interleukin-6-dependent-growth-in-a-newly-established-plasmablastic-lymphoma-cell-line-and-its-therapeutic-targets
#19
Sohtaro Mine, Tsunekazu Hishima, Akihiko Suganuma, Hitomi Fukumoto, Yuko Sato, Michiyo Kataoka, Tsuyoshi Sekizuka, Makoto Kuroda, Tadaki Suzuki, Hideki Hasegawa, Masashi Fukayama, Harutaka Katano
Plasmablastic lymphoma (PBL) is a rare, highly aggressive subtype of non-Hodgkin lymphoma with plasma-cell differentiation occurring typically in immune-suppressed patients such as those with AIDS. This study reports the establishment and characterization of a new cell line, PBL-1, derived from a patient with AIDS-associated PBL. Morphological assessment of PBL-1 indicated plasma-cell differentiation with a CD20(-) CD38(+) CD138(+) immunophenotype and IgH/c-myc translocation. The cell line harbours Epstein-Barr virus, but a 52...
August 31, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28854963/takayasu-s-arteritis-a-case-with-relapse-after-urgent-coronary-revascularization
#20
Klaus Empen, Astrid Hummel, Daniel Beug, Stephan B Felix, Mathias C Busch, Piotr M Kaczmarek
BACKGROUND: Vasculitides are commonly unrecognized causes of coronary stenosis and myocardial ischemia. We report on a 24-year old patient with Takayasu's arteritis who underwent urgent percutaneous coronary intervention, suffered from symptomatic restenosis of the left main coronary artery during standard immunosuppressive therapy. CASE PRESENTATION: A 24-year old woman was referred for coronary angiography because of typical progressive angina pectoris. On bicycle ergometry, there were both reproducible symptoms and deep ST segment depressions on precordial leads...
July 25, 2017: BMC Research Notes
keyword
keyword
5841
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"